If you’ve spent any time in the GLP-1 community you’ll have heard the one consistent gripe: the scale goes down, but so does some lean tissue along with it. The muscle-loss question has been simmering all year, and it’s one of the reasons people talk about running a GLP-1 alongside resistance training. So when a paper lands that describes a compound burning fat and shrinking fatty liver without affecting muscle mass, it gets the room’s attention.
That’s exactly what a team from the University of California, San Diego (with the Näär and Karin labs at the centre of it) reported this week in Science Advances. The compound is TOFA, which is short for 5-tetradecyloxy-2-furoic acid. It’s not a peptide and it’s not new - it’s a small molecule that’s been kicking around lipid-metabolism research for decades. What’s new is the way they’ve used it and what happens when you combine it with the usual incretin suspects.
What the compound actually does
The paper’s headline finding is in the abstract: TOFA is an orally available small molecule that promotes energy expenditure and rebalances lipid synthesis, easing obesity, abnormal glucose handling and fatty-liver disease in mice - all without cutting food intake or eating into muscle mass.
Mechanistically it’s multitargeting. It inhibits two lipogenic enzymes, ACC1 and ACC2 (acetyl-CoA carboxylases), which are the rate-limiting steps in making fat. At the same time it activates a pair of nuclear receptors, PPAR-alpha and PPAR-delta, that switch on gene programs involved in energy expenditure and lipid metabolism. So you’ve got one molecule that slows fat production while simultaneously ramping up fat burning. That’s a different lever to the GLP-1s, which mostly work upstream on appetite.
The “without affecting food intake” point matters. A lot of current obesity drugs work by making you eat less. That’s effective, but it’s also why they come with the nausea and the gastrointestinal side effect burden, and it’s part of why lean mass loss shows up - when you eat less and don’t necessarily train, some of what you lose is muscle. A molecule that shifts energy balance without needing to suppress appetite is a genuinely different angle.
The muscle point is the interesting bit
The part that makes this paper travel in fitness and peptide circles is the muscle preservation. The abstract explicitly contrasts TOFA with “current incretin-based obesity treatments” which it notes are associated with gastrointestinal side effects and muscle wasting. In the mouse studies, TOFA reduced obesity and fatty liver without affecting muscle mass.
Now, there’s an important caveat I want to put on the table up front: this is rodent data. Mice metabolise things differently, dosing in animal studies rarely scales cleanly to humans, and a lot of promising mouse obesity candidates have died in translation. What it means for us in the research-interest space is a proof of concept - that a single small molecule can hit the fat-burning side of the equation while sparing lean tissue, and that it appears to work with GLP-1s rather than competing with them.
The synergy claim
If that were the whole story it’d be neat but modest. The more eye-catching result is the interaction. The authors found TOFA acted “more than additively” with incretin analogues such as semaglutide and tirzepatide to improve obesity, dyslipidaemia and insulin resistance in the mice.
That’s the sort of finding that gets people in the community asking questions, because a large chunk of the grey-market interest in compounds sits precisely here: people already running semaglutide or tirzepatide who are looking at what else can be layered in for body composition. A molecule that tackles the fat-burning/lipid side and stacks with a GLP-1 is conceptually the kind of pairing that DIY pharmacology loves to experiment with - which is exactly why it’s worth being clear about what the science actually supports.
What the Research Says
What the evidence supports so far:
- In mice, oral TOFA reduced obesity, abnormal glucose handling and fatty-liver disease without reducing food intake or affecting muscle mass.
- The mechanism combines ACC1/ACC2 inhibition with PPAR-alpha/delta activation, targeting both fat synthesis and fat oxidation.
- In the same animal model, combining TOFA with semaglutide or tirzepatide appeared more than additive for obesity, dyslipidaemia and insulin resistance.
- This was published in Science Advances in 2026 (DOI: 10.1126/sciadv.aed3119). It is peer-reviewed rodent research, not human data.
What the evidence does NOT support:
- It does not show TOFA works in humans for weight loss, muscle preservation or anything else.
- No human safety, dosing or efficacy data exists yet for TOFA in this context.
- The “old molecule” status means there’s some prior human exposure history in other contexts, but not for chronic obesity-metabolic use.
- “More than additively” in mice is not a guarantee of meaningful combination benefit in people.
How to read this as a researcher enthusiast
If you follow peptide and metabolic research, the honest takeaway is that this is an encouraging mechanism study, not a roadmap for anything you should put in your body tomorrow. The really valuable signal is the direction: drug developers are now openly chasing muscle-sparing obesity treatments and combination approaches rather than just appetite suppression. That we’re getting papers explicitly about lean-mass preservation alongside fat loss tells you where the field’s priorities are heading.
For people already interested in how GLP-1s interact with body composition, this adds a data point to the ongoing conversation about muscle loss on incretin therapy. It’s worth filing alongside the growing literature on that exact topic - we’ve covered that debate here - because it confirms the concern is real enough that researchers are actively engineering around it.
The combination-angle also echoes what’s already happening in the research pipeline with triple agonists like retatrutide and fixed-dose pairs like CagriSema. The industry is clearly betting on multi-targeting. TOFA is just an academic illustration of the same principle from the lipid-metabolism side rather than the incretin side.
None of this is a recommendation to source or use TOFA or anything like it. Grey Highway is a research-education community - we don’t sell or supply compounds, and we’re not here to tell you what to inject. But the TOFA paper is a legitimately interesting piece of science about how obesity and fatty-liver metabolism could be tackled without the muscle cost, and it’s a useful window into where metabolic research is going in the back half of 2026.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources: Lee JY, et al. “A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders.” Science Advances, 2026. DOI: 10.1126/sciadv.aed3119. Reported by University of California news (21 Aug 2026), ScienceDaily (23 Aug 2026), ScienceAlert (26 Aug 2026) and Drug Discovery News (25 Aug 2026).